RCS - Creo Medical Group - Strategic Collaboration with Khalifa University

Creo MedicalAnnouncement

05/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240205:nRSE9140Ba&default-theme=true

RNS Number : 9140B  Creo Medical Group PLC  05 February 2024

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Strategic Collaboration with Khalifa University of Science and Technology, Abu
Dhabi

 

Creo and Khalifa University establish a Strategic Research Collaboration to
capitalise on Creo's Intellectual Property (IP) estate alongside Khalifa
University's research expertise

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy, and internationally
highly-ranked Khalifa University of Science and Technology in Abu Dhabi, have
established a strategic collaboration to explore innovative commercial
opportunities, with an initial focus on healthcare challenges relevant to the
population in the United Arab Emirates (UAE), and the wider Middle East and
North Africa region using the resources and expertise available at Khalifa
University in Abu Dhabi to capitalise on Creo's Intellectual Property (IP)
estate.

 

Having recently performed first procedures in the UAE, Creo will also leverage
the collaboration to support its regional distributors and core clinical
operations, including the development of clinical research with key customers
in Abu Dhabi and the wider region.

 

This collaboration is aligned with Khalifa University's strategic objective to
enhance enterprise targeted research with highly innovative partners. Khalifa
University's deep tech initiative encompasses research partnerships but also
investments in start-ups, incubation services, a science and technology park,
an endowment fund, and a continuing education programme. This collaboration is
also in line with the UAE Government's policy and helps further Khalifa
University's ambition to become one of the world's premier research
institutions.

 

Craig Gulliford, Chief Executive Officer of Creo Medical, said: "Creo has
broad and deep IP that underpins its Kamaptive Electrosurgical Advanced Energy
and Non-Thermal Plasma Sterilisation technology used in current products as
well as offering significant potential for future products and treatments. As
part of our strategy, we are driven to exploit our IP either directly or in
partnership with third-parties, as shown by our Robotic Assisted Surgery
collaborations. Khalifa University is a research-intensive organisation with a
similar drive to develop and commercially exploit leading technologies, at
scale and on a global basis. The combination of Creo's people, technology and
IP with Khalifa University's teams, technologies, facilities and resources
represents a great opportunity for both organisations to advance and
commercialise incremental technology and products and enhance research
profiles internationally."

 

Professor Sir John O'Reilly, President, Khalifa University, said: "We are
delighted to enter into this strategic collaboration with Creo that marks a
significant milestone in our ongoing efforts to advance medical science,
technology and innovation, seeing it taken through to commercialisation and
application to the benefit of patients. Such a collaboration between an
internationally highly-ranked university and Creo, a leader in medical device
technology, bears testament to our shared commitment to obtaining healthcare
solutions relevant to UAE and globally. By combining Creo's groundbreaking
intellectual property and Khalifa University's extensive research capabilities
and resources, we are poised to explore new opportunities and develop
impactful solutions to healthcare challenges."

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cavendish Capital Markets Limited                  +44 (0)20 7220 0500
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Broker)                      +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                                    Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                         Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

 

About Creo Medical

 

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

About Khalifa University of Science and Technology

Khalifa University of Science and Technology, the UAE's top-ranked
research-intensive institution, focuses on developing world leaders and
critical thinkers in science, engineering and medicine. The world-class
university endeavors to be a catalyst to the growth of Abu Dhabi and the UAE's
rapidly developing knowledge economy, as an education destination of choice
and a global leader among widely acknowledged international universities.

 

For more information, please visit: http://www.ku.ac.ae/
(http://www.ku.ac.ae/)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZLLFBZLLLBBD